Log in

2617 TransThera Sciences (Nanjing). Inc. HKEX · China

TransThera Sciences (Nanjing). (2617) news

TransThera Sciences (Nanjing). Inc. is a public biotech or pharmaceutical company listed on HKEX under the ticker 2617, recorded under China. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest TransThera Sciences (Nanjing). news

We have not published a story on TransThera Sciences (Nanjing). yet. When there is news, it will appear here.

Questions about TransThera Sciences (Nanjing).

What is the ticker symbol of TransThera Sciences (Nanjing).?

TransThera Sciences (Nanjing). Inc. trades under the ticker 2617 on HKEX.

Where is TransThera Sciences (Nanjing). listed?

TransThera Sciences (Nanjing). Inc. is listed on HKEX.

Which country or territory is TransThera Sciences (Nanjing). listed under?

Our directory records TransThera Sciences (Nanjing). Inc. under China.

What does TransThera Sciences (Nanjing). do?

Our directory classifies TransThera Sciences (Nanjing). Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of TransThera Sciences (Nanjing).?

The ISIN recorded for TransThera Sciences (Nanjing). Inc. is CNE100006T02.

Does aibio.space cover TransThera Sciences (Nanjing).?

aibio.space lists TransThera Sciences (Nanjing). Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to TransThera Sciences (Nanjing).?

Companies in our directory listed in the same country and business area as TransThera Sciences (Nanjing).: Jiangxi Institute of Biological Products, LongBio Pharma (Suzhou) Co., Viva Biotech Holdings, Ascletis Pharma, Shaanxi Micot Pharmaceutical Technology Co., Beijing Scitop Bio-Tech Co..

Investor discussion: TransThera Sciences (Nanjing).

Members talk about TransThera Sciences (Nanjing). (2617). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at TransThera Sciences (Nanjing)., newest first. Each line links the filing it comes from.

  1. Financings

    Share or debt issue: COMPLETION OF PLACING OF NEW H SHARES UNDER THE GENERAL MANDATE. Source

  2. Financings

    Share or debt issue: CIRCULAR OF ANNUAL GENERAL MEETING. Source

  3. Financings

    Share or debt issue: PLACING OF NEW H SHARES UNDER GENERAL MANDATE. Source

  4. Financings

    Share or debt issue: COMPLETION OF PLACING OF NEW H SHARES UNDER THE GENERAL MANDATE. Source

  5. Financings

    Share or debt issue: PLACING OF NEW H SHARES UNDER GENERAL MANDATE. Source

  6. Financings

    Share or debt issue: COMPLETION OF PLACING OF NEW H SHARES UNDER THE GENERAL MANDATE. Source

  7. Financings

    Share or debt issue: PLACING OF NEW H SHARES UNDER GENERAL MANDATE. Source

  8. Financings

    Share or debt issue: CIRCULAR OF ANNUAL GENERAL MEETING. Source

  9. Financings

    Share or debt issue: GLOBAL OFFERING. Source

Press releases

Headlines of TransThera Sciences (Nanjing).'s own announcements, newest first. Each opens the full release on the newswire that carried it.

  1. HKEXnews

    INSIDE INFORMATION ANNOUNCEMENT ISSUANCE OF THE FILING NOTICE BY THE CSRC FOR THE H SHARE FULL CIRCULATION BY THE COMPANY

  2. HKEXnews

    VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON COMMERCIALISATION OF CORE PRODUCT YOCHANRA

  3. HKEXnews

    VOLUNTARY ANNOUNCEMENT FIRST PATIENT DOSED IN PHASE II CLINICAL TRIAL OF TINENGOTINIB IN COMBINATION WITH NOVEL HORMONAL THERAPY FOR PRETREATED AND PROGRESSED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN CHINA

  4. HKEXnews

    VOLUNTARY ANNOUNCEMENT INCLUSION OF YOCHANRA (TINENGOTINIB) IN THE CSCO GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF BILIARY TRACT CANCERS (2026)

  5. HKEXnews

    INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2026

  6. HKEXnews

    VOLUNTARY ANNOUNCEMENT MARKETING APPROVAL FOR YOCHANRA (TINENGOTINIB TABLETS) GRANTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

  7. HKEXnews

    GRANT OF SHARE AWARDS AND SHARE OPTIONS UNDER THE H SHARE AWARD SCHEME

  8. HKEXnews

    VOLUNTARY ANNOUNCEMENT Approval for Conducting China Phase II Clinical Trial of TT-00973 Tablets in Combination with Firmonertinib Mesylate in the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR-Sensitive Mutations

  9. HKEXnews

    VOLUNTARY ANNOUNCEMENT Enrollment Completed in the Global Multicenter Registrational Phase III Clinical Trial of Tinengotinib Monotherapy for Patients with Advanced Cholangiocarcinoma

  10. HKEXnews

    VOLUNTARY ANNOUNCEMENT Approval Granted for Phase II Clinical Trial in China of TT-01488 Tablets in Combination with Anti-CD20 Monoclonal Antibody for the Treatment of Mantle Cell Lymphoma

  11. HKEXnews

    VOLUNTARY ANNOUNCEMENT INTENTION TO CONDUCT ON-MARKET SHARE REPURCHASE UNDER GENERAL MANDATE

  12. HKEXnews

    Terms of Reference of the Strategy Committee of the Board of Directors

  13. HKEXnews

    Terms of Reference of the Remuneration and Appraisal Committee of the Board of Directors

  14. HKEXnews

    Terms of Reference of the Nomination Committee of the Board of Directors

  15. HKEXnews

    Terms of Reference of the Audit Committee of the Board of Directors

  16. HKEXnews

    Articles of Association

  17. HKEXnews

    (1) POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 18 JUNE 2026; (2) CHANGE OF THE INDEPENDENT NON-EXECUTIVE DIRECTOR AND COMPOSITION OF BOARD COMMITTEES; (3) CANCELLATION OF THE SUPERVISORY COMMITTEE; AND (4) AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND ITS APPENDICES

  18. HKEXnews

    (1) POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 18 JUNE 2026; (2) ADOPTION OF THE H SHARE AWARD SCHEME; AND (3) AUTHORIZATION TO THE SCHEME ADMINISTRATOR TO DEAL WITH MATTERS RELATED TO THE H SHARE AWARD SCHEME

  19. HKEXnews

    VOLUNTARY ANNOUNCEMENT Appointment of Chief Operating Officer

  20. HKEXnews

    VOLUNTARY ANNOUNCEMENT TransThera Sciences (Nanjing), Inc. announces poster presentation for pivotal phase II trial clinical data of Tinengotinib monotherapy in pre-treated FGFR2-altered cholangiocarcinoma at 2026 ASCO

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open HKEX:2617 on TradingView.

Listing details

TransThera Sciences (Nanjing). Inc. is a public biotech or pharmaceutical company listed on HKEX under the ticker 2617, recorded under China. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
TransThera Sciences (Nanjing). Inc.
Ticker
2617
Listing
HKEX
Country or territory
China
Business scope
Biotechnology
ISIN
CNE100006T02
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.